Tratamento de Esclerose lateral amiotrófica em Israel — receba 3 correspondências de clínicas personalizadas

Israel hospeda atualmente ensaios clínicos avançados para a ELA, incluindo o estudo fundamental de Fase 3 do PrimeC e a Fase 3b para a terapia com células-tronco NurOwn. Esses ensaios visam a neuroinflamação e a regeneração nervosa em centros como o Sourasky Medical Center e o Hadassah Medical Center. Os pesquisadores também avaliam células-tronco autólogas NG01 e terapias gênicas baseadas em RNA para retardar a progressão da doença.

• Fase 3 PrimeC: Medicamento combinado oral direcionado à neuroinflamação, iniciando ensaios fundamentais em 2025.
• Terapia celular NurOwn: Tratamento com células-tronco autólogas com fabricação local no Sourasky Medical Center.
• Células-tronco NG01: Estudos de longo prazo em Hadassah mostram que 45% dos participantes excedem 10 anos de sobrevivência.
• Terapia AstroRx: Abordagem baseada em células usando astrócitos saudáveis para apoiar neurônios danificados.

Perspectiva do Especialista Bookimed: Os dados mostram que Israel é um local principal para ensaios específicos de mutação, particularmente para SOD1 e variantes genéticas raras. Clínicas especializadas como a liderada pela Profa. Dra. Viviean Drory no Sourasky Medical Center combinam esses protocolos experimentais com mais de 30 anos de experiência em eletrofisiologia. Essa integração muitas vezes permite que os pacientes acessem medicamentos inovadores de 6 a 12 meses antes de chegarem aos mercados internacionais mais amplos.

Consenso dos Pacientes: Os pacientes observam que o teste genético precoce é vital, pois muitos ensaios israelenses agora exigem correspondências específicas de biomarcadores. Eles também enfatizam que o processo de inscrição pode levar mais de 6 meses, tornando o registro precoce nos bancos de dados hospitalares essencial.

O tratamento padrão para ELA em Israel utiliza Riluzol e Edaravona para retardar a progressão da doença. Centros especializados como o Sourasky Medical Center (Ichilov) também oferecem Tofersen para pacientes com a mutação SOD1. Esses medicamentos são frequentemente combinados com terapias sintomáticas multidisciplinares para melhorar a qualidade de vida e a função respiratória.

• Riluzol: Antagonista do glutamato de primeira linha disponível em comprimido ou líquido para prolongar a sobrevivência.
• Edaravona: Antioxidante administrado via ciclos de infusão intravenosa para retardar o declínio funcional nos pacientes.
• Tofersen: Terapia alvo para mutações genéticas SOD1 administrada através de injeções espinhais especializadas.
• Medicamentos sintomáticos: Relaxantes musculares como Baclofeno e Tizanidina controlam espasmos dolorosos e espasticidade.

Perspectiva do Especialista Bookimed: Dados sugerem que escolher centros de alto volume como o Sourasky Medical Center, que trata mais de 400.000 pacientes anualmente, proporciona melhor acesso a protocolos avançados. A Profa. Dra. Viviean Drory nesta instalação possui mais de 35 anos de experiência em avaliação eletrofisiológica. Tal experiência é vital para o diagnóstico precoce necessário para iniciar a terapia com Edaravona de forma eficaz.

Consenso dos Pacientes: Os pacientes observam que, embora o Riluzol seja o padrão, o primeiro mês pode envolver efeitos colaterais como náuseas. Muitos enfatizam a solicitação da combinação de Riluzol e Edaravona precocemente para maximizar a estabilidade.

Israel abriga centros multidisciplinares de primeira linha para ELA no Sourasky Medical Center, Hadassah Medical Center e Sheba Medical Center. Essas instalações utilizam um modelo de balcão único. Os pacientes têm acesso a neurologistas, terapeutas respiratórios e fisioterapia em visitas únicas. Especialistas líderes como a Profa. Dra. Vivian Drory oferecem atendimento especializado.

• Sourasky Medical Center: Possui um Departamento Neuromuscular especializado liderado pela Profa. Dra. Vivian Drory.
• Hadassah Medical Center: Opera uma clínica dedicada à ELA conhecida pelo acesso a ensaios clínicos avançados.
• Sheba Medical Center: Oferece atendimento integrativo, incluindo reabilitação neurológica e monitoramento domiciliar especializado.
• Rambam Medical Center: Oferece uma unidade de hospitalização diurna de neurologia para serviços médicos neuromusculares consolidados.

Visão do Especialista Bookimed: Os centros de ELA em Israel destacam-se por integrarem a pesquisa diretamente no atendimento clínico. Por exemplo, o Hadassah Medical Center atua como líder global em pesquisa genética e ensaios com células-tronco. Embora o Sourasky (Ichilov) continue sendo uma escolha de topo para pacientes internacionais devido à sua alta classificação na Newsweek, seus especialistas como a Profa. Dra. Vivian Drory trazem mais de 35 anos de experiência especializada. Essa combinação de prática clínica de alto volume e descoberta científica ativa muitas vezes permite que os pacientes acessem protocolos experimentais mais cedo do que em muitas outras regiões.

Consenso dos pacientes: Os pacientes observam que esses centros oferecem acesso notavelmente rápido a equipes especializadas, incluindo pneumologistas e nutricionistas. Muitos valorizam a terapia da fala integrada e o suporte ventilatório no Ichilov por melhorarem significativamente a qualidade de vida diária.

Pacientes internacionais podem se inscrever em ensaios clínicos israelenses para ELA, sujeitos à aprovação do Ministério da Saúde e a cotas específicas de estudo. A participação muitas vezes requer autofinanciamento para tratamentos experimentais. Centros proeminentes como o Hadassah Medical Center e o Tel Aviv Sourasky Medical Center (Ichilov) frequentemente sediam ensaios globais de terapias com células-tronco e gênicas.

• Supervisão regulatória: O Ministério da Saúde de Israel gerencia a inscrição de estrangeiros por meio de aprovações específicas de ensaios.
• Custos potenciais: Terapias experimentais para participantes internacionais podem exigir financiamento privado significativo ou subsídios.
• Instituições líderes: O Hadassah Medical Center conduz estudos importantes sobre as terapias NG01 e AstroRx.
• Expertise especializada: A Prof. Viviean Drory no Ichilov é especializada em pesquisa genética de ELA e terapia medicamentosa.

Visão do Especialista Bookimed: Dados das principais instalações israelenses mostram uma alta concentração de pesquisa em ELA em Tel Aviv e Jerusalém. Embora o Ichilov atenda mais de 400.000 pacientes anualmente, seu departamento neuromuscular especializado frequentemente prioriza pacientes com base nas taxas de progressão. Os pacientes devem procurar ensaios com rótulos de acesso expandido. Estes geralmente oferecem mais flexibilidade para aqueles que viajam de fora da União Europeia ou da América do Norte.

Consenso dos pacientes: Os pacientes enfatizam a necessidade de orçar custos significativos de viagem e hospedagem durante ensaios de longo prazo. Muitos recomendam priorizar centros que forneçam formulários de consentimento em inglês para evitar obstáculos extras de tradução durante o processo de triagem.

Israel is a global hub for Amyotrophic Lateral Sclerosis (ALS) research. Leading hubs like Hadassah Medical Center and Sourasky Medical Center offer advanced cell therapies. Key treatments include autologous NG01 infusions and the NurOwn platform. These therapies aim to slow disease progression and extend survival.

• NG01 therapy: Uses patients' own bone marrow cells. This treatment reported a 7.2-year median survival.
• AstroRx technology: Off-the-shelf astrocytes support motor neurons. Single doses have paused disease progression.
• NurOwn platform: Re-engineered stem cells secrete neurotrophic factors. These factors protect nerves and reduce inflammation.
• Clinical specialists: Experts like Prof. Viviean Drory at Sourasky specialise in ALS palliative care.

Bookimed Expert Insight: Israeli oncology and neurology centres, such as JCI-accredited Sourasky Medical Center, serve over 400,000 patients annually. While clinical trials often have strict entry criteria, the density of university-affiliated research centres in Tel Aviv and Jerusalem creates one of the highest volumes of experimental ALS access points globally. Patients should confirm if a doctor specialises in clinical neurophysiology to ensure the most accurate disease monitoring.

Patient Consensus: Patients note that Israel is a significant biomedical hub, although stem cell treatments are considered experimental. They emphasise checking eligibility early and requesting specific cell data in writing before travel.

Israel offers targeted gene therapies for specific genetic forms of Amyotrophic Lateral Sclerosis (ALS), including the first commercially approved RNA-targeted treatments. Leading university centres in Tel Aviv and Jerusalem provide advanced genetic testing to identify mutations like SOD1. These facilities also run clinical trials for next-generation therapies.

• Tofersen therapy: Targeted treatment available for the SOD1 mutation to suppress toxic protein production.
• Genetic screening: Specialists use diagnostic testing to confirm pathogenic variants before starting targeted interventions.
• RNA-based trials: Research focuses on halting nerve cell degeneration through microRNA-126 and similar pathways.
• Advanced neurology: Experts like Professor Viviean Drory specialise in neurophysiology and clinical management of ALS.

Bookimed Expert Insight: Israeli medical centres often integrate multi-stage biological treatments. For example, Sourasky Medical Center offers stem cell therapy packages starting from A$8,750. These packages often include blood work and follow-up care. This allows patients to combine supportive biological therapies with targeted genetic diagnostic protocols at a single high-volume facility.

Patient Consensus: Patients note that genetic confirmation is essential before travelling to Israel. They emphasize that while some treatments are approved, many others are only available via clinical trials. Families value the detailed advice from competent doctors in Tel Aviv who handle complex neurological cases.

Standard disease-modifying medications for Amyotrophic Lateral Sclerosis in Israel include Riluzole and Edaravone. Specialists prescribe these through the national health basket (Sal HaBriut). Israeli neurologists focus on early administration. JCI-accredited centres like Sourasky Medical Center provide these within comprehensive neuro-palliative care frameworks.

• Riluzole protocol: Core standard medication usually offered to patients immediately following diagnosis.
• Edaravone availability: Prescribed on a case-by-case basis depending on specific clinical criteria.
• Clinical neurophysiology: Experts like Prof. Viviean Drory use electromyography to monitor treatment response.
• Integrated support: Clinics bundle medications with symptom management for spasticity and saliva control.

Bookimed Expert Insight: Israeli neurology units treat an immense volume of patients, with Hadassah Medical Center serving approximately 1,000,000 people annually. This high-volume environment allows specialists to identify which patients respond best to Edaravone versus Riluzole. Patients should confirm if their prescribed medication plan includes on-site electrophysiology monitoring. This ensures the dosage remains effective as the condition evolves.

Patient Consensus: Patients note that Riluzole is the standard starting point in Israel. They emphasize that while disease-modifying drugs are vital, additional prescriptions for cramps and sleep significantly improve daily life.

Israel manages ALS through integrated multidisciplinary hubs where neurologists, pulmonologists, and therapists coordinate care in a single visit. This one-stop shop model ensures immediate access to respiratory support, nutritional management, and speech technology. Leading facilities like Sourasky Medical Center and Hadassah Medical Center prioritise patient autonomy and comfort.

• Integrated clinics: Teams evaluate patients in one day to streamline complex specialist coordination.
• Respiratory support: Specialists initiate non-invasive ventilation early to manage nighttime fatigue and breathing.
• Nutritional care: Gastroenterologists offer feeding tubes early to maintain weight and prevent choking.
• Symptom medication: Doctors prescribe targeted drugs for muscle cramps, spasticity, and excessive saliva.

Bookimed Expert Insight: Israeli neuromuscular centres excel in high-volume care, with Sourasky Medical Center alone serving over 400,000 patients annually. Our data shows that top specialists like Dr Viviean Drory combine clinical neurophysiology with advanced electromyography. This technical depth allows for more precise symptom tracking than general clinics typical in other regions.

Patient Consensus: Patients in Israel highlight the importance of setting up eye-gaze communication devices early. They note that practical planning for home equipment and pressure care is vital before returning home to Australia.

Israel's leading ALS neurologists include Prof. Vivian Drory at Sourasky Medical Center and Prof. Dimitrios Karussis at Hadassah Medical Center. These specialists lead neuromuscular units, focusing on advanced electromyography and stem cell trials. Major Israeli centres provide multidisciplinary care for managing neurodegenerative symptoms.

• Prof. Vivian Drory: Directs the Neuromuscular Diseases Unit at Sourasky, specialising in clinical neurophysiology.
• Prof. Dimitrios Karussis: Leads neuroimmunology at Hadassah, known for clinical trials using adult stem cells.
• Dr. Amir Dori: Heads the Neuromuscular Disorders Department at Sheba Medical Center, researching protein accumulation.
• Dr. Eduard Linecki: Serves as a senior neurologist at Hadassah with over 20 years of experience.

Bookimed Expert Insight: Israeli neurology units like Ichilov and Hadassah manage massive patient volumes, often seeing 1,000,000 cases annually. This scale allows specialists to focus strictly on motor neuron diseases rather than general neurology. Professor Vivian Drory, for instance, maintains specific memberships in international research alliances for ALS, ensuring patients access global-standard palliative and drug therapies.

Patient Consensus: Patients find that choosing hospitals with integrated physiotherapy and respiratory support prevents delays. They appreciate the detailed advice from competent doctors in Tel Aviv and note that English-speaking staff simplify complex medical discussions in Israel.

Diagnostic evaluation in Israel for international ALS patients involves a multi-stage review to confirm the diagnosis and assess current function. Clinical specialists use electrophysiology and electromyography (EMG) to measure muscle and nerve electrical activity. Multi-disciplinary teams at JCI-accredited centres then design personalised drug or stem cell therapy plans.

• Record review: Specialists evaluate home-country MRI, EMG, and blood tests before patients travel.
• Neurological assessment: Doctors perform repeat examinations to track symptoms and disease progression carefully.
• Electrophysiology testing: Clinics use advanced clinical neurophysiology to confirm nerve damage patterns accurately.
• Treatment synthesis: Teams include neurologists and rehabilitation specialists to map out therapeutic roadmaps.

Bookimed Expert Insight: Israeli neurology units maintain high precision by requiring fresh EMG tests using their on-site equipment. Experts like Dr Viviean Drory at Sourasky Medical Center specialise specifically in ALS neurophysiology. Our data shows patients benefit most when they provide a documented timeline of symptom progression, as this helps specialists distinguish ALS from similar neuromuscular disorders early.

Patient Consensus: Patients in Israel note that evaluations involve a fresh neurological assessment rather than just accepting prior results. They suggest bringing complete records and planning for a multi-day process as results feed directly into treatment planning.

Israeli researchers recently identified an RNA-based gene therapy that stopped and reserved nerve cell degeneration in ALS models. This discovery targets microRNA-126 to prevent toxic protein buildup. Additionally, long-term data on Hadassah Medical Center stem cell therapy shows a 7.2-year median survival rate.

• Molecular mechanism: Researchers found microRNA-126 transfer failure causes toxic protein clumps in motor neurons.
• Nerve regeneration: Engineered microRNA-126 successfully neutralized toxins and triggered new nerve cell growth.
• Survival data: Hadassah Medical Center reported 45% of patients survived over 10 years post-diagnosis.
• Clinical trials: This programmable neuroprotection method is moving toward human trials for several diseases.

Bookimed Expert Insight: Israeli neurology excels because leading specialists combine clinical practice with high-level research. Dr Viviean Drory at Sourasky Medical Center is a specialist in clinical neurophysiology and electromyography. Her involvement in international research alliances ensures patients access diagnostic techniques that align with the latest scientific breakthroughs before they become global standards.

Patient Consensus: Patients emphasize the need to distinguish between exciting laboratory research news and treatments currently available in clinics. They recommend checking for active clinical trial listings in Israel to verify if a new therapy is accessible for international cases.